STXS$2.43
$2.50
Chart
Performance
Key Stats
AI STXS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralStereotaxis (STXS) presents a mixed investment profile. While the company is involved in a niche medical technology market with potential, its financial performance has been consistently unprofitable. Technical indicators are largely neutral to slightly bearish across various timeframes. Investors should approach with caution, focusing on any significant shifts in clinical adoption or financial turnaround.
Thematic
Stereotaxis operates in the field of robotic magnetic navigation for interventional cardiology. This sector benefits from trends in minimally invasive procedures and technological advancement in healthcare. However, the company faces challenges related to market adoption and competition.
Fundamental
Stereotaxis has a weak fundamental profile characterized by consistent operating losses, negative earnings per share, and negative free cash flow. While revenue has shown some growth historically, it hasn't translated into profitability. The company holds cash but also has debt, and its valuation multiples (P/E, P/S) are not favorable given its unprofitability.
Technical
Technical indicators for Stereotaxis show a mixed picture. While the stock has some positive signals on short-term charts (e.g., 1-hour EMAs), longer-term trends and momentum indicators are largely neutral or leaning bearish. The stock is trading below key longer-term moving averages, and oscillators suggest a lack of strong bullish momentum.
| Factor | Score |
|---|---|
| Minimally Invasive Procedures | 70 |
| Healthcare Technology Adoption | 65 |
| Market Penetration & Adoption | 40 |
| Competition & Innovation | 55 |
| Regulatory Landscape (Medical Devices) | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 25 |
| Balance Sheet Health | 50 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 55 |
| Support & Resistance | 60 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive EPS Surprise History
The company has exceeded earnings per share (EPS) estimates in 6 out of the last 8 reported quarters, demonstrating a consistent ability to outperform analyst expectations.
Below Industry P/E Ratio
The trailing Price-to-Earnings (P/E) ratio of -10.4 is not comparable for a loss-making company, but the Price-to-Sales (P/S) ratio of 8.8 is below the industry average, suggesting potential undervaluation relative to revenue generation.
Bearish Points (9)
Consistent Net Losses
The company has reported net losses for the past four fiscal years (2021-2024) and negative EPS in all reported quarters, indicating ongoing unprofitability.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is negative (-10.4 TTM, -8.6 in 2024) due to the company's persistent net losses, making traditional P/E valuation metrics unreliable and indicative of financial distress.
Calendar
August 2025
8
Next Earnings Date
H: $-0.05
A: $-0.07
L: $-0.08
H: 8.60M
A: 8.13M
L: 7.30M
Profile
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Seasonals
Price Target
4.50 USD
The 39 analysts offering 1 year price forecasts for STXS have a max estimate of 5.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major direct competitor offering 5G Home Internet, a fixed wireless broadband service that directly competes with STXS's offerings.
Weight: 95
Major direct competitor offering 5G Home Internet, a fixed wireless broadband service that directly competes with STXS's offerings.
Weight: 90
Offers 5G Home Internet and is a large incumbent telecom providing broadband services, making it a significant competitor in the broader market.
Weight: 85
The largest cable broadband provider in the US, a primary incumbent competitor for residential internet customers that STXS targets.